PRISM Stock IndexesCurrent Value% Change (Daily)% Change (Inception)Most ActiveTop % GainersTop % Losers
Cannabis$41.200.1%-58.8%SNDL 72,577TLRY 6.636%CLVR -4.369%
EV$60.20-1%-39.8%NKLA 12,007IDEX 6.038%FUV -8.509%
Gene Therapy$61.00-0.1%-39.0%BLUE 6,577WVE 13.697%PGEN -9.883%
MedDevices$175.700.5%75.7%ATRS 5,230MLSS 14.152%OBLN -5.864%
MedDiagnostics$105.201.6%5.2%OPK 4,888THMO 52.121%TTOO -13.28%
Solar$84.30-1.4%-15.7%HYSR 4,805OEG 2.348%DQ -5.397%
Uranium$72.30-0.9%-27.7%UEC 15,858NXE 0.286%LEU -2.347%
Vaccines & Cell Therapy$230.000.5%130.0%SRNE 10,417MESO 10.769%APDN -3.884%
Web 3.0$40.40-3.9%-59.6%MARA 11,802SNII 3.33%PBTS -13.688%

The waiver allows the sale in 34 Texas counties of higher-volatility, winter-grade gasoline. The Biden administration has released emergency oil stocks and is considering lifting…
[Read More]

Prism Daily

Bitfarms (BITF) Shoots Up 17% in Big Day for Web 3.0 Index

Bitfarms (BITF) shot up 17% for the day, following a couple of highlights for the company. Recently, Bitfarms released their recap for their first Analyst & Investor Day, where they shared information about the company, how it works, and the…

SunPower (SPWR) Slides 11% on Weak Solar Outlook

SunPower (SPWR) fell around 11% today as the stock was initiated at Underweight by a Wells Fargo analyst. The reason behind the weak outlook is unsupported U.S. solar policies and a slowing housing market. “SunPower’s business is mostly direct sales,…

Kezar Life Sciences (KZR) Shoots Up 43% On Promising Study Data

Kezar Life Sciences (KZR) soared 43% today as it has announced promising top-line data from their phase II study, called MISSION, evaluating its lead pipeline candidate in patients with active lupus nephritis (LN). LN is a type of kidney diseased…

CEO3in60 VIDEOS

CEO3in60 Logo

Learn About Tomorrow’s Leading Companies Straight From The Source

The modern investor needs trusted, relevant information, delivered quickly and concisely. CEO3in60 provides a platform for management to succinctly share their company’s value proposition in their own words. We take the CEOs of the most dynamic up and coming companies and put them in front of the camera to provide you with the top three reasons why you should be paying attention to their business, all in less than sixty seconds.

Asensus Surgical

Asensus Surgical (NYSE American: ASXC) is leading the digital surgical market with Performance-Guided Surgery™, which enhances the work of surgeons using state-of-the-art robotics, augmented intelligence and machine learning. Shameze Rampertab, Chief Financial Officer at Asensus, outlines three value drivers for investors that will have the market paying attention in the coming months.

Soligenix

Soligenix (NASDAQ: SNGX) is developing and commercializing products to treat rare diseases in oncology and dermatology where there is an unmet medical need. Chris Schaber, President and CEO of Soligenix, Inc. spends one minute outlining three value drivers that will have investors

Read more about Soligenix, Inc.

This Week's Feature

Oxford BioDynamics: A Winning Trifecta of Technology, Story and Strong Management

Jon Burrows, CEO of Oxford Biodynamics

Biotechnology company, Oxford BioDynamics (AIM:OBD), is poised for successful commercialization of its precision medicine tests for oncology.

Any seasoned investor will tell you that investing in biotechnology companies comes with an exhilarating balance of risk and reward. If a company is successful in getting its products to market, there is potential for significant investment gains. The complex nature of biotech, and the highly regulated environment in which it operates, can make it difficult for investors to assess the probability of a company’s success.

How do investors measure value in biotechs? The first element investors typically consider is a company’s technology. Is it promising? Is it a discovery made by a well-known and respected institution? Will it solve a problem or change lives for the better? Does it have a good chance of achieving commercial success?

A second measure of value for many investors, often including the most seasoned investors, is a significant market opportunity and a compelling story. OBD’s story is focused on improving outcomes for cancer patients, but also features value drivers – such as its partnerships with leading institutions, collaborations with pharma, strong technology portfolio, commercially available tests for precision medicine and a unique 3D genomic knowledgebase – that will pique investor interest.

(more…)

Traders Lens

Japanese Yen

The Japanese Yen has been hitting historic lows against the US Dollar over the last few months.  White the trend remains down, there are some signs of at least a short-term bottom forming and it may be an opportunity to either lighten up a short position or establish a modest long position with some caution.

[More Traders Lens]

Prism View

Quoin (NASDAQ:QNRX) Shares on the Move as Company Announces First Clinical Site Open to Evaluate Netherton Syndrome Treatment

In a significant step forward for rare disease treatment, Quoin Pharmaceuticals announced the opening of the first clinical site for its Netherton Syndrome study. The specialty pharma and biotech focused on rare and orphan diseases is well-positioned to potentially deliver…

Oxford BioDynamics: A Winning Trifecta of Technology, Story and Strong Management

Biotechnology company, Oxford BioDynamics (AIM:OBD), is poised for successful commercialization of its precision medicine tests for oncology. Any seasoned investor will tell you that investing in biotechnology companies comes with an exhilarating balance of risk and reward. If a company…

The Ascension of Asensus in Performance-Guided Surgery

Key commercial and regulatory milestones expected during the second half of 2022 In a recent interview, Shameze Rampertab, CFO of Asensus Surgical (NYSE American: ASXC), shared more of the Performance-Guided Surgery™ company’s 2022 plans and progress. Asensus developed and commercialized…

$VBHI: Investing in Energy & Petroleum is One Way. Investing in Mineral Assets is a Better Way

Shared Reserves, Not Expenses Verde Bio Holdings (OTCQB: VBHI) is a trusted oil and gas mineral…

(Nasdaq:SNGX) Offers New Hope and Research for Rare Form of Non-Hodgkins Lymphoma

While cutaneous T-cell lymphoma or CTCL—a rare form of non-Hodgkin’s lymphoma— currently has no FDA-approved first-line…

Soligenix Moves Forward with Treatments for Cutaneous T-Cell Lymphoma and Psoriasis

Strategy supports global need and has potential use in growing home healthcare market Rising to the…

Lexaria Grants Exclusive License to Premier Wellness Science for Japanese Market

Expanding its footprint in the Japanese health and wellness market, Lexaria Bioscience (NASDAQ:LEXX), has signed an…